bentracimab
-
Malvern’s PhaseBio Enjoys ‘a Truly Momentous Occasion’ with Licensing Agreement Worth Up to $245 Million
Malvern-based PhaseBio Pharmaceuticals has signed an exclusive licensing agreement valued up to $245 million with Alfasigma of Italy, writes John George for the Philadelphia Business…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
